Digital medicines company Proteus Digital Health has announced the completion of its Series G financing, raising over $172 million and adding more institutional investors. The company announced this past June the first part of this funding series with $120 million from new investors based in the U.S., Europe and Asia. The funding will enable Proteus to advance the manufacturing and commercialization of its products, which have the potential to significantly improve the effectiveness of existing pharmaceutical treatments.
Its core technology—the digital health feedback system—provides a view into an individual’s personal health choices and physiologic response, allowing patients to better manage their health and more effectively collaborate with caregivers and clinicians. Proteus' last equity round was a $62.5 million Series F raised in May 2013, which gave the company a $427 million valuation at the time. Existing backers include Novartis, Adams Street Partners and Frazier Healthcare, among others.